Genetics/Genomics/Proteomics of Gastric Adenocarcinoma

Gastroenterology Clinics of North America

Volumn 42, Issue 2, 2013, Pages 241-260

  Uppal, Dushant S ^a   Powell, Steven M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Gastric cancer; Genomics; Hereditary gastric cancer; Molecular genetics; Proteomics

Indexed keywords

ARGONAUTE 2 PROTEIN; CADHERIN; CD44V6 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; MICRORNA; MICRORNA 187; MICRORNA 371; MICRORNA 378; MYC PROTEIN; OSTEOPONTIN; OXALIPLATIN; PLATELET DERIVED GROWTH FACTOR A; PROTEIN BAX; PROTEIN BCL 2; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TIE 1 RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA1; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; UVOMORULIN; VASCULOTROPIN;

APOPTOSIS; BAX GENE; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PROGNOSIS; CANCER SUSCEPTIBILITY; CANCER THERAPY; CHROMOSOMAL INSTABILITY; DISEASE ASSOCIATION; DISEASE MARKER; DNA METHYLATION; FAMILIAL CANCER; GENE; GENE MUTATION; GENOMICS; HUMAN; MET GENE; MICROSATELLITE INSTABILITY; POLYPOSIS; POLYPOSIS SYNDROME; PROTEIN BLOOD LEVEL; PROTEOMICS; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; TFF1 GENE;

ADENOCARCINOMA; CADHERINS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENOMIC INSTABILITY; GENOMICS; HUMANS; NEOPLASTIC SYNDROMES, HEREDITARY; PROTEIN ARRAY ANALYSIS; PROTEIN KINASES; PROTEIN TYROSINE PHOSPHATASES; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84877060960     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2013.01.005     Document Type: Review

References (155)

1. Goldgar D.E., Easton D.F., Cannon-Albright L.A., et al. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994, 86:1600-1608.
2. Lugli A., Zlobec I., Singer G., et al. Napoleon Bonaparte's gastric cancer: a clinicopathologic approach to staging, pathogenesis, and etiology. Nat Clin Pract Gastroenterol Hepatol 2007, 4:52-57.
3. Antommarchi F. Les derniers moments de Napoleon, en compement du memorial de Sainte-Helene 1825, H Tarlier, Brusselles (Belgium). 1st edition.
4. Hemminki K., Jiang Y. Familial and second gastric carcinomas: a nationwide epidemiologic study from Sweden. Cancer 2002, 94:1157-1165.
5. Zanghieri G., Di Gregorio C., Sacchetti C., et al. Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. Cancer 1990, 66:2047-2051.
6. Palli D., Galli M., Caporaso N.E., et al. Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev 1994, 3:15-18.
7. Lee F.I. Carcinoma of the gastric antrum in identical twins. Postgrad Med J 1971, 47:622-624.
8. Aoki M., Yamamoto K., Noshiro H., et al. A full genome scan for gastric cancer. J Med Genet 2005, 42:83-87.
9. Fitzgerald R.C., Hardwick R., Huntsman D., et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 2010, 47:436-444.
10. Guilford P., Hopkins J., Harraway J., et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998, 392:402-405.
11. Blair V.R. Familial gastric cancer: genetics, diagnosis, and management. Surg Oncol Clin N Am 2012, 21:35-56.
12. Barber M., Murrell A., Ito Y., et al. Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. J Pathol 2008, 216:295-306.
13. Schrader K., Huntsman D. Hereditary diffuse gastric cancer. Cancer Treat Res 2010, 155:33-63.
14. Oliveira C., Senz J., Kaurah P., et al. Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet 2009, 18:1545-1555.
15. Guilford P.J., Hopkins J.B., Grady W.M., et al. E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat 1999, 14:249-255.
16. Pharoah P.D., Guilford P., Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001, 121:1348-1353.
17. Kluijt I., Siemerink E.J., Ausems M.G., et al. CDH1-related hereditary diffuse gastric cancer syndrome: clinical variations and implications for counseling. Int J Cancer 2012, 131:367-376.
18. Kaurah P., MacMillan A., Boyd N., et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007, 297:2360-2372.
19. Humar B., Blair V., Charlton A., et al. E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. Cancer Res 2009, 69:2050-2056.
20. Oliveira C., Sousa S., Pinheiro H., et al. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology 2009, 136:2137-2148.
21. Norton J.A., Ham C.M., Van Dam J., et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007, 245:873-879.
22. Brooks-Wilson A.R., Kaurah P., Suriano G., et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 2004, 41:508-517.
23. Ascano J.J., Frierson H., Moskaluk C.A., et al. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. Mod Pathol 2001, 14:942-949.
24. Corso G., Pedrazzani C., Pinheiro H., et al. E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer. Eur J Cancer 2011, 47:631-639.
25. Stone J., Bevan S., Cunningham D., et al. Low frequency of germline E-cadherin mutations in familial and nonfamilial gastric cancer. Br J Cancer 1999, 79:1935-1937.
26. Caldas C., Carneiro F., Lynch H.T., et al. Familial gastric cancer: overview and guidelines for management. J Med Genet 1999, 36:873-880.
27. Lynch H.T., Grady W., Suriano G., et al. Gastric cancer: new genetic developments. J Surg Oncol 2005, 90:114-133. [discussion: 33].
28. Pinheiro H., Bordeira-Carrico R., Seixas S., et al. Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum Mol Genet 2010, 19:943-952.
29. Capelle L.G., Van Grieken N.C., Lingsma H.F., et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 2010, 138:487-492.
30. Aarnio M., Salovaara R., Aaltonen L.A., et al. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int J Cancer 1997, 74:551-555.
31. Masciari S., Dewanwala A., Stoffel E.M., et al. Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med 2011, 13:651-657.
32. Varley J.M., McGown G., Thorncroft M., et al. An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. J Med Genet 1995, 32:942-945.
33. Kleihues P., Schauble B., zur Hausen A., et al. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 1997, 150:1-13.
34. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 2005, 7:60.
35. van Lier M.G., Westerman A.M., Wagner A., et al. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut 2011, 60:141-147.
36. Offerhaus G.J., Giardiello F.M., Krush A.J., et al. The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 1992, 102:1980-1982.
37. Win A.K., Hopper J.L., Jenkins M.A. Association between monoallelic MUTYH mutation and colorectal cancer risk: a meta-regression analysis. Fam Cancer 2011, 10:1-9.
38. Pollock J., Welsh J.S. Clinical cancer genetics: part I: gastrointestinal. Am J Clin Oncol 2011, 34:332-336.
39. Hizawa K., Iida M., Yao T., et al. Juvenile polyposis of the stomach: clinicopathological features and its malignant potential. J Clin Pathol 1997, 50:771-774.
40. Heald B., Mester J., Rybicki L., et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology 2010, 139:1927-1933.
41. Stanich P.P., Francis D.L., Sweetser S. The spectrum of findings in Cowden syndrome. Clin Gastroenterol Hepatol 2011, 9:e2-e3.
42. Maimon S.N., Zinninger M.M. Familial gastric cancer. Gastroenterology 1953, 25:139-152. [discussion: 53-5].
43. Woolf C.M., Isaacson E.A. An analysis of 5 " stomach cancer families" in the state of Utah. Cancer 1961, 14:1005-1016.
44. Dellavecchia C., Guala A., Olivieri C., et al. Early onset of gastric carcinoma and constitutional deletion of 18p. Cancer Genet Cytogenet 1999, 113:96-99.
45. Lee J.H., Han S.U., Cho H., et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000, 19:4947-4953.
46. Oliveira C., Seruca R., Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. Int J Surg Pathol 2006, 14:21-33.
47. Gayther S.A., Gorringe K.L., Ramus S.J., et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res 1998, 58:4086-4089.
48. McDonald S.A., Greaves L.C., Gutierrez-Gonzalez L., et al. Mechanisms of field cancerization in the human stomach: the expansion and spread of mutated gastric stem cells. Gastroenterology 2008, 134:500-510.
49. Sasaki O., Soejima K., Korenaga D., et al. Comparison of the intratumor DNA ploidy distribution pattern between differentiated and undifferentiated gastric carcinoma. Anal Quant Cytol Histol 1999, 21:161-165.
50. Seruca R., Castedo S., Correia C., et al. Cytogenetic findings in eleven gastric carcinomas. Cancer Genet Cytogenet 1993, 68:42-48.
51. Panani A.D., Ferti A., Malliaros S., et al. Cytogenetic study of 11 gastric adenocarcinomas. Cancer Genet Cytogenet 1995, 81:169-172.
52. El-Rifai W., Harper J.C., Cummings O.W., et al. Consistent genetic alterations in xenografts of proximal stomach and gastro-esophageal junction adenocarcinomas. Cancer Res 1998, 58:34-37.
53. Kimura Y., Noguchi T., Kawahara K., et al. Genetic alterations in 102 primary gastric cancers by comparative genomic hybridization: gain of 20q and loss of 18q are associated with tumor progression. Mod Pathol 2004, 17:1328-1337.
54. Hidaka S., Yasutake T., Kondo M., et al. Frequent gains of 20q and losses of 18q are associated with lymph node metastasis in intestinal-type gastric cancer. Anticancer Res 2003, 23:3353-3357.
55. Yustein A.S., Harper J.C., Petroni G.R., et al. Allelotype of gastric adenocarcinoma. Cancer Res 1999, 59:1437-1441.
56. Schneider B.G., Pulitzer D.R., Brown R.D., et al. Allelic imbalance in gastric cancer: an affected site on chromosome arm 3p. Genes Chromosomes Cancer 1995, 13:263-271.
57. Rumpel C.A., Powell S.M., Moskaluk C.A. Mapping of genetic deletions on the long arm of chromosome 4 in human esophageal adenocarcinomas. Am J Pathol 1999, 154:1329-1334.
58. Leite M., Corso G., Sousa S., et al. MSI phenotype and MMR alterations in familial and sporadic gastric cancer. Int J Cancer 2011, 128:1606-1613.
59. dos Santos N.R., Seruca R., Constancia M., et al. Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. Gastroenterology 1996, 110:38-44.
60. Halling K.C., Harper J., Moskaluk C.A., et al. Origin of microsatellite instability in gastric cancer. Am J Pathol 1999, 155:205-211.
61. Suzuki H., Itoh F., Toyota M., et al. Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. Int J Cancer 1999, 83:309-313.
62. Yamamoto H., Perez-Piteira J., Yoshida T., et al. Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology 1999, 116:1348-1357.
63. Myeroff L.L., Parsons R., Kim S.J., et al. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 1995, 55:5545-5547.
64. Mori Y., Sato F., Selaru F.M., et al. Instabilotyping reveals unique mutational spectra in microsatellite-unstable gastric cancers. Cancer Res 2002, 62:3641-3645.
65. Yamamoto H., Sawai H., Perucho M. Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res 1997, 57:4420-4426.
66. Gil J., Yamamoto H., Zapata J.M., et al. Impairment of the proapoptotic activity of Bax by missense mutations found in gastrointestinal cancers. Cancer Res 1999, 59:2034-2037.
67. Powell S.M. Stomach cancer. Metabolic and molecular basis of inherited diseases 2001, 1119-1124. McGraw-Hill Companies, Inc, New York. 8th edition. B. Childs, K.W. Kinzler, B. Vogelstein (Eds.).
68. Wu M.S., Shun C.T., Wang H.P., et al. Loss of pS2 protein expression is an early event of intestinal-type gastric cancer. Jpn J Cancer Res 1998, 89:278-282.
69. Lefebvre O., Chenard M.P., Masson R., et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 1996, 274:259-262.
70. Nogueira A.M., Machado J.C., Carneiro F., et al. Patterns of expression of trefoil peptides and mucins in gastric polyps with and without malignant transformation. J Pathol 1999, 187:541-548.
71. Nishizuka S., Tamura G., Terashima M., et al. Loss of heterozygosity during the development and progression of differentiated adenocarcinoma of the stomach. J Pathol 1998, 185:38-43.
72. Calnan D.P., Westley B.R., May F.E., et al. The trefoil peptide TFF1 inhibits the growth of the human gastric adenocarcinoma cell line AGS. J Pathol 1999, 188:312-317.
73. Beckler A.D., Roche J.K., Harper J.C., et al. Decreased abundance of trefoil factor 1 transcript in the majority of gastric carcinomas. Cancer 2003, 98:2184-2191.
74. Sankpal N.V., Moskaluk C.A., Hampton G.M., et al. Overexpression of CEBPbeta correlates with decreased TFF1 in gastric cancer. Oncogene 2006, 25:643-649.
75. Howlett M., Judd L.M., Jenkins B., et al. Differential regulation of gastric tumor growth by cytokines that signal exclusively through the coreceptor gp130. Gastroenterology 2005, 129:1005-1018.
76. May F.E., Griffin S.M., Westley B.R. The trefoil factor interacting protein TFIZ1 binds the trefoil protein TFF1 preferentially in normal gastric mucosal cells but the co-expression of these proteins is deregulated in gastric cancer. Int J Biochem Cell Biol 2009, 41:632-640.
77. Moss S.F., Lee J.W., Sabo E., et al. Decreased expression of gastrokine 1 and the trefoil factor interacting protein TFIZ1/GKN2 in gastric cancer: influence of tumor histology and relationship to prognosis. Clin Cancer Res 2008, 14:4161-4167.
78. Birchmeier W., Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994, 1198:11-26.
79. Mayer B., Johnson J.P., Leitl F., et al. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res 1993, 53:1690-1695.
80. Becker K.F., Atkinson M.J., Reich U., et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994, 54:3845-3852.
81. Berx G., Becker K.F., Hofler H., et al. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 1998, 12:226-237.
82. Gschwind A., Fischer O.M., Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004, 4:361-370.
83. Nakamura K., Yashiro M., Matsuoka T., et al. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology 2006, 131:1530-1541.
84. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501.
85. Samuels Y., Wang Z., Bardelli A., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
86. Li V.S., Wong C.W., Chan T.L., et al. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 2005, 5:29.
87. Kang M.J., Ryu B.K., Lee M.G., et al. NF-kappaB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signaling, to promote gastric tumorigenesis. Gastroenterology 2008, 135:2030-2042. 2042.e1-3.
88. Sakakura C., Hagiwara A., Yasuoka R., et al. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 2001, 84:824-831.
89. Wang Z., Shen D., Parsons D.W., et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004, 304:1164-1166.
90. Lee J.W., Jeong E.G., Lee S.H., et al. Mutational analysis of PTPRT phosphatase domains in common human cancers. APMIS 2007, 115:47-51.
91. El-Rifai W., Smith M.F., Li G., et al. Gastric cancers overexpress DARPP-32 and a novel isoform, t-DARPP. Cancer Res 2002, 62:4061-4064.
92. Belkhiri A., Zaika A., Pidkovka N., et al. Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas. Cancer Res 2005, 65:6583-6592.
93. Nakajima M., Sawada H., Yamada Y., et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999, 85:1894-1902.
94. Tsugawa K., Yonemura Y., Hirono Y., et al. Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology 1998, 55:475-481.
95. Toyota M., Ahuja N., Suzuki H., et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999, 59:5438-5442.
96. Chi X.Z., Yang J.O., Lee K.Y., et al. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol 2005, 25:8097-8107.
97. Ito K., Liu Q., Salto-Tellez M., et al. RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 2005, 65:7743-7750.
98. Mishra R., Powell S.M. Gastric cancer: molecular biology. Gastrointestinal oncology: principles and practice 2008, 245-255. Lippincott, Williams & Wilkins, Philadelphia. D.P. Kelsen, J.M. Daly, S.E. Kern (Eds.).
99. Ouyang H., Furukawa T., Abe T., et al. The BAX gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium. Clin Cancer Res 1998, 4:1071-1074.
100. Lee J.W., Jeong E.G., Soung Y.H., et al. Decreased expression of tumour suppressor Bax-interacting factor-1 (Bif-1), a Bax activator, in gastric carcinomas. Pathology 2006, 38:312-315.
101. Kondo S., Shinomura Y., Miyazaki Y., et al. Mutations of the bak gene in human gastric and colorectal cancers. Cancer Res 2000, 60:4328-4330.
102. Kuraoka K., Matsumura S., Sanada Y., et al. A single nucleotide polymorphism in the extracellular domain of TRAIL receptor DR4 at nucleotide 626 in gastric cancer patients in Japan. Oncol Rep 2005, 14:465-470.
103. Hollstein M., Shomer B., Greenblatt M., et al. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 1996, 24:141-146.
104. Bao W., Fu H.J., Xie Q.S., et al. HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology 2011, 141:2076-2087.e6.
105. Kim J., Sohn S., Chae Y., et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann Oncol 2007, 18(6):1030-1036.
106. Kastury K., Baffa R., Druck T., et al. Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res 1996, 56:978-983.
107. Ohta M., Inoue H., Cotticelli M.G., et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996, 84:587-597.
108. Baffa R., Veronese M.L., Santoro R., et al. Loss of FHIT expression in gastric carcinoma. Cancer Res 1998, 58:4708-4714.
109. Gemma A., Hagiwara K., Ke Y., et al. FHIT mutations in human primary gastric cancer. Cancer Res 1997, 57:1435-1437.
110. Jones S., Li M., Parsons D.W., et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat 2012, 33:100-103.
111. Powell S.M., Harper J.C., Hamilton S.R., et al. Inactivation of Smad4 in gastric carcinomas. Cancer Res 1997, 57:4221-4224.
112. Park W.S., Moon Y.W., Yang Y.M., et al. Mutations of the STK11 gene in sporadic gastric carcinoma. Int J Oncol 1998, 13:601-604.
113. Nagase H., Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat 1993, 2:425-434.
114. Park W.S., Oh R.R., Park J.Y., et al. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res 1999, 59:4257-4260.
115. Ma X., Chen K., Huang S., et al. Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis 2005, 26:1698-1705.
116. Fukaya M., Isohata N., Ohta H., et al. Hedgehog signal activation in gastric pit cell and in diffuse-type gastric cancer. Gastroenterology 2006, 131:14-29.
117. Zhang Y.Z., Zhang L.H., Gao Y., et al. Discovery and validation of prognostic markers in gastric cancer by genome-wide expression profiling. World J Gastroenterol 2011, 17:1710-1717.
118. Shi D., Wang S., Gu D., et al. The PSCA polymorphisms derived from genome-wide association study are associated with risk of gastric cancer: a meta-analysis. J Cancer Res Clin Oncol 2012, 138:1339-1345.
119. Du W., Wang S., Zhou Q., et al. ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer. Oncogene 2012, 10.1038/onc.2012.359.
120. Kuroda A., Tsukamoto Y., Nguyen L.T., et al. Genomic profiling of submucosal-invasive gastric cancer by array-based comparative genomic hybridization. PLoS One 2011, 6:e22313.
121. El-Rifai W., Moskaluk C.A., Abdrabbo M.K., et al. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 2002, 62:6823-6826.
122. Song J.H., Meltzer S.J. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology 2012, 143:35-47.e2.
123. Liu W., Liu B., Cai Q., et al. Proteomic identification of serum biomarkers for gastric cancer using multi-dimensional liquid chromatography and 2D differential gel electrophoresis. Clin Chim Acta 2012, 413:1098-1106.
124. Oh H.K., Tan A.L., Das K., et al. Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. Clin Cancer Res 2011, 17:2657-2667.
125. Petrocca F., Visone R., Onelli M.R., et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 2008, 13:272-286.
126. Kim Y.H., Liang H., Liu X., et al. AMPKalpha modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. Cancer Res 2012, 72:2512-2521.
127. Lee B.L., Lee H.S., Jung J., et al. Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer. Clin Cancer Res 2005, 11:2518-2525.
128. Sohma I., Fujiwara Y., Sugita Y., et al. Parthenolide, an NF-kappaB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer. Cancer Genomics Proteomics 2011, 8:39-47.
129. Boussioutas A., Li H., Liu J., et al. Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res 2003, 63:2569-2577.
130. Gerke V., Creutz C.E., Moss S.E. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 2005, 6:449-461.
131. Melle C., Ernst G., Schimmel B., et al. Characterization of pepsinogen C as a potential biomarker for gastric cancer using a histo-proteomic approach. J Proteome Res 2005, 4:1799-1804.
132. Kwon O.H., Park S.J., Kang T.W., et al. Elevated fibroblast growth factor-inducible 14 expression promotes gastric cancer growth via nuclear factor-kappaB and is associated with poor patient outcome. Cancer Lett 2012, 314:73-81.
133. Kim H.K., Reyzer M.L., Choi I.J., et al. Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. J Proteome Res 2010, 9:4123-4130.
134. Hatakeyama K., Ohshima K., Fukuda Y., et al. Identification of a novel protein isoform derived from cancer-related splicing variants using combined analysis of transcriptome and proteome. Proteomics 2011, 11:2275-2282.
135. Jung J.H., Kim H.J., Yeom J., et al. Lowered expression of galectin-2 is associated with lymph node metastasis in gastric cancer. J Gastroenterol 2012, 47:37-48.
136. Wang D., Ye F., Sun Y., et al. Protein signatures for classification and prognosis of gastric cancer: a signaling pathway-based approach. Am J Pathol 2011, 179:1657-1666.
137. Gravalos C., Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008, 19:1523-1529.
138. Allgayer H., Babic R., Gruetzner K.U., et al. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000, 18:2201-2209.
139. Tanner M., Hollmen M., Junttila T.T., et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005, 16:273-278.
140. Guan X.Y., Fu S.B., Xia J.C., et al. Recurrent chromosome changes in 62 primary gastric carcinomas detected by comparative genomic hybridization. Cancer Genet Cytogenet 2000, 123:27-34.
141. Weiss M.M., Kuipers E.J., Postma C., et al. Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol 2004, 26:307-317.
142. Nishigaki R., Osaki M., Hiratsuka M., et al. Proteomic identification of differentially-expressed genes in human gastric carcinomas. Proteomics 2005, 5:3205-3213.
143. Cascinu S., Graziano F., Del Ferro E., et al. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 1998, 83:1917-1922.
144. Saito H., Tsujitani S., Ikeguchi M., et al. Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer. Oncology 1999, 56:253-258.
145. Muguruma K., Nakata B., Hirakawa K., et al. Gan To Kagaku Ryoho 1998, 25(Suppl 3):400-403. [in Japanese].
146. Nakata B., Muguruma K., Hirakawa K., et al. Predictive value of Bcl-2 and Bax protein expression for chemotherapeutic effect in gastric cancer. A pilot study. Oncology 1998, 55:543-547.
147. Kim J.W., Im S.A., Kim M., et al. The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen. Anticancer Res 2012, 32:1547-1553.
148. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
149. Gofuku J., Shiozaki H., Doki Y., et al. Characterization of soluble E-cadherin as a disease marker in gastric cancer patients. Br J Cancer 1998, 78:1095-1101.
150. De Vita F., Orditura M., Galizia G., et al. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. Cancer 1999, 86:1936-1943.
151. Han S.U., Lee J.H., Kim W.H., et al. Significant correlation between serum level of hepatocyte growth factor and progression of gastric carcinoma. World J Surg 1999, 23:1176-1180.
152. Yoshikawa T., Saitoh M., Tsuburaya A., et al. Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma. A possible marker for serosal invasion and metastasis. Cancer 1999, 86:1929-1935.
153. Wu C.Y., Wu M.S., Chiang E.P., et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 2007, 56:782-789.
154. Poon T.C., Sung J.J., Chow S.M., et al. Diagnosis of gastric cancer by serum proteomic fingerprinting. Gastroenterology 2006, 130:1858-1864.
155. Liu H., Zhu L., Liu B., et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett 2012, 316:196-203.